Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2009

Open Access 01-12-2009 | Research article

Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas

Authors: Lovisa Österberg, Kristina Levan, Karolina Partheen, Ulla Delle, Björn Olsson, Karin Sundfeldt, György Horvath

Published in: BMC Cancer | Issue 1/2009

Login to get access

Abstract

Background

Chemotherapy resistance remains a major obstacle in the treatment of women with ovarian cancer. Establishing predictive markers of chemoresponse would help to individualize therapy and improve survival of ovarian cancer patients. Chemotherapy resistance in ovarian cancer has been studied thoroughly and several non-overlapping single genes, gene profiles and copy number alterations have been suggested as potential markers. The objective of this study was to explore genetic alterations behind chemotherapy resistance in ovarian cancer with the ultimate aim to find potential predictive markers.

Methods

To create the best opportunities for identifying genetic alterations of importance for resistance, we selected a homogenous tumor material concerning histology, stage and chemotherapy. Using high-resolution whole genome array comparative genomic hybridization (CGH), we analyzed the tumor genomes of 40 fresh-frozen stage III ovarian serous carcinomas, all uniformly treated with combination therapy paclitaxel/carboplatin. Fisher's exact test was used to identify significant differences. Subsequently, we examined four genes in the significant regions (EVI1, MDS1, SH3GL2, SH3KBP1) plus the ABCB1 gene with quantitative real-time polymerase chain reaction (QPCR) to evaluate the impact of DNA alterations on the transcriptional level.

Results

We identified gain in 3q26.2, and losses in 6q11.2-12, 9p22.3, 9p22.2-22.1, 9p22.1-21.3, Xp22.2-22.12, Xp22.11-11.3, and Xp11.23-11.1 to be significantly associated with chemotherapy resistance. In the gene expression analysis, EVI1 expression differed between samples with gain versus without gain, exhibiting higher expression in the gain group.

Conclusion

In conclusion, we detected specific genetic alterations associated with resistance, of which some might be potential predictive markers of chemotherapy resistance in advanced ovarian serous carcinomas. Thus, further studies are required to validate these findings in an independent ovarian tumor series.
Appendix
Available only for authorised users
Literature
1.
McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M: Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol. 1996, 23 (5 Suppl 12): 40-47.PubMed
2.
Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, et al: Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000, 92 (9): 699-708. 10.1093/jnci/92.9.699.CrossRefPubMed
3.
Heintz APM, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngain HYS, Pecorelli S, Beller U: Carcinoma of the ovary. Int J Gynaecol Obstet. 2006, 95 Suppl 1: S161-S192. 10.1016/S0020-7292(06)60033-7.CrossRefPubMed
4.
Nogales E, Wolf SG, Downing KH: Structure of the alpha beta tubulin dimer by electron crystallography. Nature. 1998, 391 (6663): 199-203. 10.1038/34465.CrossRefPubMed
5.
Galletti E, Magnani M, Renzulli ML, Botta M: Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes. ChemMedChem. 2007, 2 (7): 920-942. 10.1002/cmdc.200600308.CrossRefPubMed
6.
Luqmani YA: Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract. 2005, 14 (Suppl 1): 35-48. 10.1159/000086183.PubMed
7.
Barry MA, Behnke CA, Eastman A: Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol. 1990, 40 (10): 2353-2362. 10.1016/0006-2952(90)90733-2.CrossRefPubMed
8.
Ferry KV, Hamilton TC, Johnson SW: Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol. 2000, 60 (9): 1305-1313. 10.1016/S0006-2952(00)00441-X.CrossRefPubMed
9.
Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC, Zunino F: Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res. 1996, 56 (3): 556-562.PubMed
10.
Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, Anderson ME: High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA. 1992, 89 (7): 3070-3074. 10.1073/pnas.89.7.3070.CrossRefPubMedPubMedCentral
11.
Katano K, Safaei R, Samimi G, Holzer A, Rochdi M, Howell SB: The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells. Mol Pharmacol. 2003, 64 (2): 466-473. 10.1124/mol.64.2.466.CrossRefPubMed
12.
Bernardini M, Lee CH, Beheshti B, Prasad M, Albert M, Marrano P, Begley H, Shaw P, Covens A, Murphy J, et al: High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer. Neoplasia. 2005, 7 (6): 603-613. 10.1593/neo.04760.CrossRefPubMedPubMedCentral
13.
Kim SW, Kim JW, Kim YT, Kim JH, Kim S, Yoon BS, Nam EJ, Kim HY: Analysis of chromosomal changes in serous ovarian carcinoma using high-resolution array comparative genomic hybridization: Potential predictive markers of chemoresistant disease. Genes Chromosomes Cancer. 2007, 46 (1): 1-9. 10.1002/gcc.20384.CrossRefPubMed
14.
Prasad M, Bernardini M, Tsalenko A, Marrano P, Paderova J, Lee CH, Ben-Dor A, Barrett MT, Squire JA: High definition cytogenetics and oligonucleotide aCGH analyses of cisplatin-resistant ovarian cancer cells. Genes Chromosomes Cancer. 2008, 47 (5): 427-436. 10.1002/gcc.20547.CrossRefPubMed
15.
Osterberg L, Levan K, Partheen K, Staaf J, Sundfeldt K, Horvath G: High-resolution genomic profiling of carboplatin resistance in early-stage epithelial ovarian carcinoma. Cytogenet Genome Res. 2009, 125 (1): 8-18. 10.1159/000218744.CrossRefPubMed
16.
Kudoh K, Takano M, Koshikawa T, Hirai M, Yoshida S, Mano Y, Yamamoto K, Ishii K, Kita T, Kikuchi Y, et al: Gains of 1q21-q22 and 13q12-q14 are potential indicators for resistance to cisplatin-based chemotherapy in ovarian cancer patients. Clin Cancer Res. 1999, 5 (9): 2526-2531.PubMed
17.
Wasenius VM, Jekunen A, Monni O, Joensuu H, Aebi S, Howell SB, Knuutila S: Comparative genomic hybridization analysis of chromosomal changes occurring during development of acquired resistance to cisplatin in human ovarian carcinoma cells. Genes Chromosomes Cancer. 1997, 18 (4): 286-291. 10.1002/(SICI)1098-2264(199704)18:4<286::AID-GCC6>3.0.CO;2-X.CrossRefPubMed
18.
Takano M, Kudo K, Goto T, Yamamoto K, Kita T, Kikuchi Y: Analyses by comparative genomic hybridization of genes relating with cisplatin-resistance in ovarian cancer. Hum Cell. 2001, 14 (4): 267-271.PubMed
19.
Osterberg L, Levan K, Partheen K, Helou K, Horvath G: Cytogenetic analysis of carboplatin resistance in early-stage epithelial ovarian carcinoma. Cancer Genet Cytogenet. 2005, 163 (2): 144-150. 10.1016/j.cancergencyto.2005.06.023.CrossRefPubMed
20.
Jonsson G, Staaf J, Olsson E, Heidenblad M, Vallon-Christersson J, Osoegawa K, de Jong P, Oredsson S, Ringner M, Hoglund M, et al: High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization. Genes Chromosomes Cancer. 2007, 46 (6): 543-558. 10.1002/gcc.20438.CrossRefPubMed
21.
Saal LH, Troein C, Vallon-Christersson J, Gruvberger S, Borg A, Peterson C: BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data. Genome Biology. 2002, 3 (8): 10.1186/gb-2002-3-8-software0003.
22.
Staaf J, Jonsson G, Ringner M, Vallon-Christersson J: Normalization of array-CGH data: influence of copy number imbalances. BMC Genomics. 2007, 8: 382-10.1186/1471-2164-8-382.CrossRefPubMedPubMedCentral
23.
Autio R, Hautaniemi S, Kauraniemi P, Yli-Harja O, Astola J, Wolf M, Kallioniemi A: CGH-Plotter: MATLAB toolbox for CGH-data analysis. Bioinformatics. 2003, 19 (13): 1714-1715. 10.1093/bioinformatics/btg230.CrossRefPubMed
24.
Gunnarsson R, Staaf J, Jansson M, Ottesen AM, Goransson H, Liljedahl U, Ralfkiaer U, Mansouri M, Buhl AM, Smedby KE, et al: Screening for copy-number alterations and loss of heterozygosity in chronic lymphocytic leukemia--a comparative study of four differently designed, high resolution microarray platforms. Genes Chromosomes Cancer. 2008, 47 (8): 697-711. 10.1002/gcc.20575.CrossRefPubMed
25.
Willenbrock H, Fridlyand J: A comparison study: applying segmentation to array CGH data for downstream analyses. Bioinformatics. 2005, 21 (22): 4084-4091. 10.1093/bioinformatics/bti677.CrossRefPubMed
26.
Frank E, Hall M, Trigg L, Holmes G, Witten IH: Data mining in bioinformatics using Weka. Bioinformatics. 2004, 20 (15): 2479-2481. 10.1093/bioinformatics/bth261.CrossRefPubMed
27.
Partheen K, Levan K, Osterberg L, Helou K, Horvath G: Analysis of cytogenetic alterations in stage III serous ovarian adenocarcinoma reveals a heterogeneous group regarding survival, surgical outcome, and substage. Genes Chromosomes Cancer. 2004, 40 (4): 342-348. 10.1002/gcc.20053.CrossRefPubMed
28.
Gehan EA: A Generalized Wilcoxon Test for Comparing Arbitrarily Singly-Censored Samples. Biometrika. 1965, 52: 203-223.CrossRefPubMed
29.
Partheen K, Levan K, Osterberg L, Horvath G: Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors. Eur J Cancer. 2006, 42 (16): 2846-2854. 10.1016/j.ejca.2006.06.026.CrossRefPubMed
30.
Nanjundan M, Nakayama Y, Cheng KW, Lahad J, Liu J, Lu K, Kuo WL, Smith-McCune K, Fishman D, Gray JW, et al: Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer Res. 2007, 67 (7): 3074-3084. 10.1158/0008-5472.CAN-06-2366.CrossRefPubMed
31.
Sunde JS, Donninger H, Wu K, Johnson ME, Pestell RG, Rose GS, Mok SC, Brady J, Bonome T, Birrer MJ: Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian cancer. Cancer Res. 2006, 66 (17): 8404-8412. 10.1158/0008-5472.CAN-06-0683.CrossRefPubMed
32.
Brooks DJ, Woodward S, Thompson FH, Dos Santos B, Russell M, Yang JM, Guan XY, Trent J, Alberts DS, Taetle R: Expression of the zinc finger gene EVI-1 in ovarian and other cancers. Br J Cancer. 1996, 74 (10): 1518-1525.CrossRefPubMedPubMedCentral
33.
Liu Y, Chen L, Ko TC, Fields AP, Thompson EA: Evi1 is a survival factor which conveys resistance to both TGFbeta- and taxol-mediated cell death via PI3K/AKT. Oncogene. 2006, 25 (25): 3565-3575. 10.1038/sj.onc.1209403.CrossRefPubMed
34.
Soubeyran P, Kowanetz K, Szymkiewicz I, Langdon WY, Dikic I: Cbl-CIN85-endophilin complex mediates ligand-induced downregulation of EGF receptors. Nature. 2002, 416 (6877): 183-187. 10.1038/416183a.CrossRefPubMed
35.
Cao C, Lu S, Sowa A, Kivlin R, Amaral A, Chu W, Yang H, Di W, Wan Y: Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs. Cancer Lett. 2008, 266 (2): 249-262. 10.1016/j.canlet.2008.02.062.CrossRefPubMedPubMedCentral
36.
Chan JK, Pham H, You XJ, Cloven NG, Burger RA, Rose GS, Van Nostrand K, Korc M, Disaia PJ, Fan H: Suppression of ovarian cancer cell tumorigenicity and evasion of Cisplatin resistance using a truncated epidermal growth factor receptor in a rat model. Cancer Res. 2005, 65 (8): 3243-3248.PubMed
37.
Huang KC, Rao PH, Lau CC, Heard E, Ng SK, Brown C, Mok SC, Berkowitz RS, Ng SW: Relationship of XIST expression and responses of ovarian cancer to chemotherapy. Mol Cancer Ther. 2002, 1 (10): 769-776.PubMed
38.
Hartmann LC, Lu KH, Linette GP, Cliby WA, Kalli KR, Gershenson D, Bast RC, Stec J, Iartchouk N, Smith DI, et al: Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res. 2005, 11 (6): 2149-2155. 10.1158/1078-0432.CCR-04-1673.CrossRefPubMed
39.
Tetu B, Popa I, Bairati I, L'Esperance S, Bachvarova M, Plante M, Harel F, Bachvarov D: Immunohistochemical analysis of possible chemoresistance markers identified by micro-arrays on serous ovarian carcinomas. Mod Pathol. 2008, 21 (8): 1002-1010. 10.1038/modpathol.2008.80.CrossRefPubMed
40.
Yang YL, Chu JY, Luo ML, Wu YP, Zhang Y, Feng YB, Shi ZZ, Xu X, Han YL, Cai Y, et al: Amplification of PRKCI, located in 3q26, is associated with lymph node metastasis in esophageal squamous cell carcinoma. Genes Chromosomes Cancer. 2008, 47 (2): 127-136. 10.1002/gcc.20514.CrossRefPubMed
41.
Gray JW, Suzuki S, Kuo WL, Polikoff D, Deavers M, Smith-McCune K, Berchuck A, Pinkel D, Albertson D, Mills GB: Specific keynote: genome copy number abnormalities in ovarian cancer. Gynecol Oncol. 2003, 88 (1 Pt 2): s16-21. 10.1006/gyno.2002.6677. discussion S22-14.CrossRefPubMed
42.
Larramendy ML, Lushnikova T, Bjorkqvist AM, Wistuba II, Virmani AK, Shivapurkar N, Gazdar AF, Knuutila S: Comparative genomic hybridization reveals complex genetic changes in primary breast cancer tumors and their cell lines. Cancer Genet Cytogenet. 2000, 119 (2): 132-138. 10.1016/S0165-4608(99)00226-5.CrossRefPubMed
43.
Nucifora G, Laricchia-Robbio L, Senyuk V: EVI1 and hematopoietic disorders: history and perspectives. Gene. 2006, 368: 1-11. 10.1016/j.gene.2005.09.020.CrossRefPubMed
44.
Yokoi S, Yasui K, Iizasa T, Imoto I, Fujisawa T, Inazawa J: TERC identified as a probable target within the 3q26 amplicon that is detected frequently in non-small cell lung cancers. Clin Cancer Res. 2003, 9 (13): 4705-4713.PubMed
45.
Morishita K, Parganas E, Douglass EC, Ihle JN: Unique expression of the human Evi-1 gene in an endometrial carcinoma cell line: sequence of cDNAs and structure of alternatively spliced transcripts. Oncogene. 1990, 5 (7): 963-971.PubMed
46.
Fears S, Mathieu C, Zeleznik-Le N, Huang S, Rowley JD, Nucifora G: Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family. Proc Natl Acad Sci USA. 1996, 93 (4): 1642-1647. 10.1073/pnas.93.4.1642.CrossRefPubMedPubMedCentral
47.
Kaye SB: Reversal of drug resistance in ovarian cancer: where do we go from here?. J Clin Oncol. 2008, 26 (16): 2616-2618. 10.1200/JCO.2008.16.2123.CrossRefPubMed
48.
Wang YC, Juric D, Francisco B, Yu RX, Duran GE, Chen GK, Chen X, Sikic BI: Regional activation of chromosomal arm 7q with and without gene amplification in taxane-selected human ovarian cancer cell lines. Genes Chromosomes Cancer. 2006, 45 (4): 365-374. 10.1002/gcc.20300.CrossRefPubMed
49.
Yabuki N, Sakata K, Yamasaki T, Terashima H, Mio T, Miyazaki Y, Fujii T, Kitada K: Gene amplification and expression in lung cancer cells with acquired paclitaxel resistance. Cancer Genet Cytogenet. 2007, 173 (1): 1-9. 10.1016/j.cancergencyto.2006.07.020.CrossRefPubMed
50.
Kitada K, Yamasaki T: The complicated copy number alterations in chromosome 7 of a lung cancer cell line is explained by a model based on repeated breakage-fusion-bridge cycles. Cancer Genet Cytogenet. 2008, 185 (1): 11-19. 10.1016/j.cancergencyto.2008.04.005.CrossRefPubMed
51.
Codegoni AM, Broggini M, Pitelli MR, Pantarotto M, Torri V, Mangioni C, D'Incalci M: Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer. Gynecol Oncol. 1997, 65 (1): 130-137. 10.1006/gyno.1996.4609.CrossRefPubMed
Metadata
Title
Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas
Authors
Lovisa Österberg
Kristina Levan
Karolina Partheen
Ulla Delle
Björn Olsson
Karin Sundfeldt
György Horvath
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2009
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-9-368

Other articles of this Issue 1/2009

BMC Cancer 1/2009 Go to the issue

Research article

Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer

Research article

Enhanced antitumor efficacy of cisplatin in combination with HemoHIM in tumor-bearing mice

Research article

Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus ≥10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial

Research article

Long term survival following the detection of circulating tumour cells in head and neck squamous cell carcinoma

Research article

A non-randomized comparison of gemcitabine-based chemoradiation with or without induction chemotherapy for locally advanced squamous cell carcinoma of the head and neck

Research article

The association between RCAS1 expression in laryngeal and pharyngeal cancer and its healthy stroma with cancer relapse
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits